Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborator:
Medivation, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01974765
First received: October 25, 2013
Last updated: June 9, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)